Alimera Sciences Inc
NASDAQ:ALIM
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Alimera Sciences Inc
NASDAQ:ALIM
|
290.2m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
524.9B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
220.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.5B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.6B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Alimera Sciences Inc
Glance View
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. The company is headquartered in Alpharetta, Georgia and currently employs 145 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. The firm focuses on diseases affecting the retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant that treats patients by delivering a continuous microdose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. The Company’s product ILUVIEN is also used for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is also used in the European Economic Area (EEA) to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The firm commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Alimera Sciences Inc is 0.2%, which is above its 3-year median of -9.9%.
Over the last 3 years, Alimera Sciences Inc’s Operating Margin has decreased from 8.7% to 0.2%. During this period, it reached a low of -22.7% on Sep 30, 2022 and a high of 8.7% on May 30, 2021.